CY1113069T1 - Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου - Google Patents

Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου

Info

Publication number
CY1113069T1
CY1113069T1 CY20121100722T CY121100722T CY1113069T1 CY 1113069 T1 CY1113069 T1 CY 1113069T1 CY 20121100722 T CY20121100722 T CY 20121100722T CY 121100722 T CY121100722 T CY 121100722T CY 1113069 T1 CY1113069 T1 CY 1113069T1
Authority
CY
Cyprus
Prior art keywords
powder
preparation
methods
synthesis
dry powder
Prior art date
Application number
CY20121100722T
Other languages
English (en)
Inventor
David Morton
Martin Shott
Rebecca Davies
Original Assignee
Vectura Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113069(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Limited filed Critical Vectura Limited
Publication of CY1113069T1 publication Critical patent/CY1113069T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τον αντιμουσκαρινικό παράγοντα γλυκοπυρρολικό, για παράδειγμα το άλας βρωμιούχου γλυκοπυρρονίου. Ιδιαιτέρως, η παρούσα εφεύρεση αφορά σε συνθέσεις ξηρής σκόνης που δεικνύουν βελτιωμένη σταθερότητα συναρτήσει του χρόνου και μεθόδους για παρασκευή αυτών.
CY20121100722T 2004-04-30 2012-08-13 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου CY1113069T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
EP05738040A EP1755555B1 (en) 2004-04-30 2005-04-29 Methods for preparing dry powder compositions of glycopyrrolate

Publications (1)

Publication Number Publication Date
CY1113069T1 true CY1113069T1 (el) 2015-08-05

Family

ID=32408337

Family Applications (6)

Application Number Title Priority Date Filing Date
CY20121100722T CY1113069T1 (el) 2004-04-30 2012-08-13 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY2013012C CY2013012I1 (el) 2004-04-30 2013-03-29 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY2014015C CY2014015I1 (el) 2004-04-30 2014-03-19 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY20151100754T CY1116655T1 (el) 2004-04-30 2015-08-27 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015060C CY2015060I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015059C CY2015059I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου

Family Applications After (5)

Application Number Title Priority Date Filing Date
CY2013012C CY2013012I1 (el) 2004-04-30 2013-03-29 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY2014015C CY2014015I1 (el) 2004-04-30 2014-03-19 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY20151100754T CY1116655T1 (el) 2004-04-30 2015-08-27 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015060C CY2015060I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015059C CY2015059I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου

Country Status (27)

Country Link
US (1) US20080063719A1 (el)
EP (3) EP2422766B1 (el)
JP (2) JP5000483B2 (el)
KR (1) KR101287919B1 (el)
CN (3) CN102008453A (el)
AU (2) AU2005237266B2 (el)
BR (1) BRPI0510500B8 (el)
CA (1) CA2563760C (el)
CY (6) CY1113069T1 (el)
DK (2) DK1755555T3 (el)
ES (2) ES2388289T3 (el)
GB (1) GB0409703D0 (el)
HK (2) HK1095282A1 (el)
HU (4) HUE025463T2 (el)
IL (2) IL178651A (el)
LT (1) LTC2422766I2 (el)
LU (2) LU92176I2 (el)
MX (2) MXPA06012493A (el)
NO (1) NO20065502L (el)
NZ (1) NZ550479A (el)
PL (2) PL2422766T3 (el)
PT (2) PT1755555E (el)
RU (1) RU2396943C2 (el)
SG (3) SG10201605001SA (el)
SI (2) SI2422766T1 (el)
WO (1) WO2005105043A2 (el)
ZA (1) ZA200609350B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
PT2234595E (pt) * 2007-12-13 2013-01-24 Novartis Ag Processo para redução da tendência de um sal de glicopirrónio para se agregar durante a armazenagem
CA2707594C (en) * 2007-12-13 2015-08-18 Novartis Ag Process for preparing particulates of crystalline drug substance
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
PL2400950T3 (pl) 2009-02-26 2019-12-31 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
US20120101077A1 (en) * 2009-04-24 2012-04-26 Schering Corporation Agglomerate formulations useful in dry powder inhalers
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
MX2012011179A (es) * 2010-03-31 2013-03-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica en polvo para inhalacion.
EP2762133A1 (en) 2010-04-01 2014-08-06 CHIESI FARMACEUTICI S.p.A. Process for preparing carrier particles for dry powders for inhalation
NO2560611T3 (el) * 2010-04-21 2018-06-02
WO2012028663A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP2611422B1 (en) 2010-08-31 2018-10-31 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
ES2699257T3 (es) 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US20140275517A1 (en) † 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
BR112017003888B1 (pt) * 2014-09-09 2022-11-16 Vectura Limited Método de fabricação de uma formulação de pó seco
AR102305A1 (es) * 2014-10-16 2017-02-15 Teva Branded Pharmaceutical Products R&D Inc Procedimiento para preparar formulación farmacéutica inhalable de polvo seco
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
JP6741774B2 (ja) 2016-03-08 2020-08-19 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン
JP6741773B2 (ja) 2016-03-08 2020-08-19 メレオ バイオファーマ １ リミテッド 炎症状態の急性増悪の治療のための投与レジメン
US10888500B2 (en) 2016-07-29 2021-01-12 Inke, S.A. Particle size stabilization process
ES2957459T3 (es) 2016-09-19 2024-01-19 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
WO2018167180A1 (en) * 2017-03-15 2018-09-20 Vectura Limited Method and formulation
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
AU2018382895B2 (en) 2017-12-11 2024-05-16 Mereo Biopharma 1 Limited Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
DK3585383T3 (da) 2017-12-11 2021-04-19 Mereo Biopharma 1 Ltd Anvendelse af 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamid i forebyggelsen af akutte forværringer af kronisk obstruktiv lungesygdom
KR20200078162A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
EP1131059B1 (de) * 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
WO2002000197A1 (en) 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
DK2283818T3 (en) * 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
PT2283817T (pt) * 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
AU2002234476B2 (en) * 2001-03-30 2006-04-27 Jagotec Ag Medical aerosol formulations
EP1501479A1 (en) * 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use

Also Published As

Publication number Publication date
SG10201605001SA (en) 2016-08-30
AU2011200543B2 (en) 2012-11-29
CY2014015I2 (el) 2015-12-09
IL178651A (en) 2012-12-31
RU2006142322A (ru) 2008-06-20
SI2422766T1 (sl) 2015-10-30
CA2563760A1 (en) 2005-11-10
WO2005105043A2 (en) 2005-11-10
KR101287919B1 (ko) 2013-07-18
ZA200609350B (en) 2008-04-30
HK1167334A1 (en) 2012-11-30
PL1755555T3 (pl) 2012-11-30
HUE025463T2 (en) 2016-02-29
IL223545A0 (en) 2013-02-03
EP1755555B1 (en) 2012-05-23
SI1755555T1 (sl) 2012-10-30
CY2013012I2 (el) 2015-08-05
CY2015060I1 (el) 2020-05-29
HUS1300006I1 (hu) 2016-07-28
DK2422766T3 (da) 2015-08-31
PT1755555E (pt) 2012-08-17
RU2396943C2 (ru) 2010-08-20
CA2563760C (en) 2013-07-02
AU2011200543A1 (en) 2011-03-03
CY2015059I1 (el) 2020-05-29
HUS1500072I1 (hu) 2016-02-29
BRPI0510500B1 (pt) 2019-04-24
SG186673A1 (en) 2013-01-30
GB0409703D0 (en) 2004-06-02
CY1116655T1 (el) 2017-03-15
EP2422766A3 (en) 2012-04-25
ES2388289T3 (es) 2012-10-11
EP2422766A2 (en) 2012-02-29
CN102008453A (zh) 2011-04-13
US20080063719A1 (en) 2008-03-13
PT2422766E (pt) 2015-10-12
PL2422766T3 (pl) 2015-11-30
LU92176I2 (fr) 2013-05-27
NO20065502L (no) 2007-01-24
DK1755555T3 (da) 2012-08-20
WO2005105043A3 (en) 2006-05-04
AU2005237266A1 (en) 2005-11-10
LTC2422766I2 (lt) 2020-02-10
EP1755555A2 (en) 2007-02-28
IL223545A (en) 2016-04-21
MX341426B (es) 2016-08-18
MXPA06012493A (es) 2007-01-29
AU2005237266B2 (en) 2010-11-11
EP2422766B1 (en) 2015-06-24
IL178651A0 (en) 2007-02-11
KR20070033978A (ko) 2007-03-27
JP5124718B2 (ja) 2013-01-23
AU2011200543A8 (en) 2011-03-31
CY2014015I1 (el) 2015-12-09
SG152292A1 (en) 2009-05-29
CN1964700A (zh) 2007-05-16
EP2422767A3 (en) 2012-04-25
LU92392I2 (fr) 2015-11-02
JP2007535522A (ja) 2007-12-06
NZ550479A (en) 2009-11-27
ES2546982T3 (es) 2015-09-30
BRPI0510500A (pt) 2007-10-30
JP5000483B2 (ja) 2012-08-15
JP2012031209A (ja) 2012-02-16
BRPI0510500B8 (pt) 2021-05-25
CY2013012I1 (el) 2015-08-05
EP2422767A2 (en) 2012-02-29
CN107252423A (zh) 2017-10-17
HUS1500073I1 (hu) 2016-02-29
LU92176I9 (el) 2019-01-04
HK1095282A1 (en) 2007-05-04

Similar Documents

Publication Publication Date Title
CY1113069T1 (el) Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY1108306T1 (el) Αναστολεις αζαϊνδολιου των mtp και apob
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1113533T1 (el) Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
CY1109369T1 (el) Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
EA200701771A1 (ru) Низкомолекулярные ингибиторы mdm2 и их применение
DE602004012083D1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
EA200700699A1 (ru) Ингибиторы взаимодействия между mdm2 и p53
SE0301653D0 (sv) Novel compounds
CY1115078T1 (el) Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης
ME00997B (me) 2'-fluor-2 ' -deoksitetrahidrouridini kao inhibitori citidin deaminaze
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
NO20071823L (no) Testosterongeler omfattende polypropylenglykol som gjennomtrengningsforsterker
EA200801414A1 (ru) Кальцилитические соединения
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение